10 Best Diabetes Stocks To Buy According to Billionaires

6. DexCom, Inc. (NASDAQ:DXCM)

Number of Billionaires: 15

Dollar Value of Billionaire Holdings: $1,347,351,505

DexCom, Inc. (NASDAQ:DXCM), founded in 1999 and headquartered in San Diego, is a leader in diabetes care, specializing in Continuous Glucose Monitoring (CGM) systems. Its wearable devices, like the Dexcom G6 and G7, provide real-time glucose monitoring without finger pricks, transmitting data to smartphones and smartwatches for better diabetes management. The company generates revenue through direct device sales, software integrations, and partnerships with automated insulin delivery systems like Tandem Diabetes Care and Beta Bionics.

DexCom, Inc. (NASDAQ:DXCM) reported strong financial results for Q4 and fiscal year 2024, demonstrating consistent growth despite some challenges. Their Q4 revenue reached $1.11 billion, an 8% increase year-over-year, with international sales seeing a significant 17% rise. Gross profit, however, decreased to 59.4% of revenue, impacted by higher production costs and a non-cash charge. Operating income also declined due to increased strategic investments, but net income remained solid at $177.8 million, or $0.45 per share.

For the full year, DexCom, Inc. (NASDAQ:DXCM)’s total revenue rose by 11% to $4.03 billion, which was fueled by both U.S. and international growth. The company also expanded its product portfolio, adding over 140,000 users for its new over-the-counter Stelo CGM within four months. Additionally, the business secured key reimbursement wins, including coverage for Dexcom ONE+ in France and expanded U.S. coverage for non-insulin-dependent diabetes patients. Looking ahead, DexCom, Inc. (NASDAQ:DXCM)’s continued innovation is highlighted by its FDA submission for the G7 15-day CGM system, with approval expected in late 2025.